p62Dok Antibody #3912
- WB
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Transfected Only |
| MW (kDa) | 62 |
| SOURCE | Rabbit |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Protocol
Specificity / Sensitivity
p62Dok Antibody detects transfected levels of p62Dok proteins. The antibody does not cross-react with related proteins.
Species Reactivity:
Human
The antigen sequence used to produce this antibody shares 100% sequence homology with the species listed here, but reactivity has not been tested or confirmed to work by CST. Use of this product with these species is not covered under our Product Performance Guarantee.
Species predicted to react based on 100% sequence homology:
Mouse
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Tyr398 of human p62Dok. Antibodies are purified by protein A and peptide affinity chromatography.
Background
p62Dok (Dok-1) is a major tyrosine-phosphorylated, GAP-associated, 60 kDa protein present within the cells transformed by different tyrosine kinases (1). p62Dok contains an amino-terminal pleckstrin homology domain potentially involved in phospholipid interaction and membrane targeting, a central putative phospho-tyrosine binding domain for interacting with tyrosine-phosphorylated proteins. There are numerous tyrosines in its carboxy-terminal region that are potential targets for tyrosine kinases. If phosphorylated, these tyrosines could serve as docking sites for proteins that contain an SH2 domain (2). Overexpression of p62Dok has been shown to inhibit Ras activity in human embryonic kidney 293 cells and B cell antigen receptor-mediated c-Fos promoter activation in an immature B cell line (3), suggesting that p62Dok may play a negative role in Ras signaling. Moreover, p62Dok overexpression may also inhibit insulin-stimulated Akt activation (4).
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.